当前蛋白身份:P28501 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 配体/离子不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1AE8 HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP 提交 1997-03-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 AZL 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;277 K;PEG 4000 15%, PH 7.0, 5X10-3 M AZALYS-DERIVATIVE, 277 K.
分辨率 2.00 Å
1AFE HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP 提交 1997-03-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 ALZ 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;PEG 4000 15%, PH 7.0, 5X10-3 M AZALYS COMPOUND
分辨率 2.00 Å
1AHT CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION 提交 1995-03-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) APA (2S)-3-(4-carbamimidoylphenyl)-2-hydroxypropanoic acid × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 1.60 Å
1AI8 HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG 提交 1997-05-01 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) T42 MORPHOLINO-DIPHENYLALANINE-METHOXYPROPYLBORONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.2;277 K;PROTEIN COMPLEX WAS CRYSTALLIZED FROM 25% PEG 8000 0.05 SODIUM PHOSPHATE, PH 7.2, TEMPERATURE 277 K.
分辨率 1.85 Å R-free 0.240
1AWF NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT 提交 1997-10-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) GR4 R3-ACETOXY-17-(1-FORMYL-5-METHYL-3-OXO-HEX-4-ENYL)-12,16-DIHYDROXY-14-HYDROXYMETHYL-4,10,13-TRIMETHYL-2,3,4,5,6,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-4-CARBOXYLIC ACID IDOPYRANOSYL ESTER × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 22% PEG4K, 200MM NACL. THE SOLUTION CONTAINED 25%DMSO. PROTEIN CONCENTRATION OF 5MG/ML.
分辨率 2.20 Å
1D3D CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4 提交 1999-09-29 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 54–65(12 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 2 BZT 3-(3-BROMO-4-PYRROLIDIN-1-YLMETHYL-BENZYL)-2-[4-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-BENZO[B]THIOPHEN-6-OL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;30% PEG 3400, 100MM SODIUM CITRATE, 200 MM AMMONIUM ACETATE, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 2.04 Å R-free 0.223
1D3P CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3 提交 1999-09-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 54–65(12 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 2 BT3 3-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-BENZYL]-2-4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL] -BENZO[B]THIOPHEN-6-OL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;30% PEG3400; 100mM sodium citrate; 200 mM ammonium acetate, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 2.10 Å R-free 0.214
1D3Q CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2 提交 1999-09-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 54–65(12 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 2 BT2 3-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-BENZYL]-2-4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL] -BENZO[B]THIOPHENE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;30% PEG3400; 100 mM sodium citrate; 200 mM ammonium acetate, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 2.90 Å R-free 0.228
1D3T CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1 提交 1999-09-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 54–65(12 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 2 BT1 {2-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-BENZO[B]THIOPHEN-3-YL}-[4-(2-PYRROLIDIN-1-YL-ETHOXY)-PHENYL]-METHANONE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;30% PEG 3400; 100 mM sodium citrate; 200 mM ammonium acetate, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 277K
分辨率 3.00 Å R-free 0.235
1D4P CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5-AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR 提交 1999-10-04 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 54–65(12 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 NA SODIUM ION × 2 BPP 2-(4-benzylpiperidine-1-carbonyl)-1H-indole-5-carboximidamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 5.6;277 K;30% PEG 4000, 150 mM sodium citrate, 200 mM ammonium acetate, pH 5.6, VAPOR DIFFUSION, temperature 277K
分辨率 2.07 Å R-free 0.231
1NO9 Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. 提交 2003-01-16 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–65(11 aa) 片段:Chain I
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 4ND N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;PEG 4000, Sodium Chloride, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
分辨率 1.90 Å R-free 0.204
1QHR NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS 提交 1999-05-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) 157 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 22% PEG4K, 200MM NACL. PROTEIN CONCENTRATION OF 5MG/ML.
分辨率 2.20 Å
1QJ1 Novel Covalent Active Site Thrombin Inhibitors 提交 1999-06-21 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa) 片段:PEPTIDE FRAGMENT OF HIRUDIN
非标准单体:是(mmCIF未提供具体位点) 166 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 22% PEG4K, 200MM NACL. PROTEIN CONCENTRATION OF 5MG/ML.
分辨率 2.00 Å
1QJ6 Novel Covalent Active Site Thrombin Inhibitors 提交 1999-06-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa) 片段:PEPTIDE FRAGMENT OF HIRUDIN
非标准单体:是(mmCIF未提供具体位点) 167 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 22% PEG4K, 200MM NACL. PROTEIN CONCENTRATION OF 5MG/ML.
分辨率 2.20 Å
1QJ7 Novel Covalent Active Site Thrombin Inhibitors 提交 1999-06-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa) 片段:PEPTIDE FRAGMENT OF HIRUDIN
非标准单体:是(mmCIF未提供具体位点) GR1 6-CARBAMIMIDOYL-2-[5-(3-DIETHYLCARBAMOYL-PHENYL)-2-HYDROXY-INDAN-1-YL]-HEXANOIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 22% PEG4K, 200MM NACL. PROTEIN CONCENTRATION OF 5MG/ML.
分辨率 2.20 Å
1UMA ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE 提交 1996-03-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 I 55–64(10 aa)
非标准单体:是(mmCIF未提供具体位点) NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 IN2 N,N-DIMETHYLCARBAMOYL-ALPHA-AZALYSINE × 2 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.00 Å
2UUF Thrombin-hirugen binary complex at 1.26A resolution 提交 2007-03-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 55–64(10 aa) 片段:RESIDUES 55-64
非标准单体:是(mmCIF未提供具体位点) NA SODIUM ION × 1 CA CALCIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 28% PEG4K, 500MM NACL.
分辨率 1.26 Å R-free 0.194
2UUJ Thrombin-hirugen-gw473178 ternary complex at 1.32A resolution 提交 2007-03-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 55–64(10 aa) 片段:RESIDUES 55-64
非标准单体:是(mmCIF未提供具体位点) NA SODIUM ION × 1 CA CALCIUM ION × 1 896 N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALLIZATION CONDITIONS: CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 28% PEG4K, 500MM NACL.
分辨率 1.32 Å R-free 0.211
2UUK Thrombin-hirugen-gw420128 ternary complex at 1.39A resolution 提交 2007-03-03 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 H 55–64(10 aa) 片段:RESIDUES 55-64
非标准单体:是(mmCIF未提供具体位点) NA SODIUM ION × 1 CA CALCIUM ION × 1 897 N-[3-(TERT-BUTYLAMINO)-3-OXOPROPYL]-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;CRYSTALLIZATION CONDITIONS: CRYSTALS WERE GROWN BY MACROSEEDING A SOLUTION OF 100MM HEPES PH 7.0, 28% PEG4K,500MM NACL.
分辨率 1.39 Å R-free 0.173